Literature DB >> 1750265

Acute respiratory infections in Australian Aboriginal children: current knowledge and future requirements.

J Hanna1, P Torzillo.   

Abstract

Although inadequately documented, it is clear that acute respiratory infection (ARI) is a major cause of morbidity and hospitalization in Australian Aboriginal children. ARIs continue to cause substantial mortality in Aboriginal children, and they are likely to cause a variety of potentially serious sequelae. The literature emphasizes the importance of pneumonia as a cause of hospitalization of Aboriginal children. There is good evidence that Streptococcus pneumoniae and Haemophilus influenzae are predominant causes of severe pneumonia, but little is known about the importance of other respiratory pathogens, such as respiratory syncytial virus, as causes of ARI in Aboriginal children. Poor living conditions, low birthweight and malnutrition are likely to be important risk factors for ARI in some groups of Aboriginal children. Although broad-ranging economic and environmental changes will be required to bring about a sustained reduction in ARI in Aboriginal children, there should be an emphasis upon correct case management of ARI at the primary care level so as to reduce the need for hospitalization. Some research priorities are discussed.

Entities:  

Mesh:

Year:  1991        PMID: 1750265

Source DB:  PubMed          Journal:  P N G Med J        ISSN: 0031-1480


  2 in total

1.  Effectiveness of 7-valent pneumococcal conjugate vaccine against radiologically diagnosed pneumonia in indigenous infants in Australia.

Authors:  K F O'Grady; J B Carlin; A B Chang; P J Torzillo; T M Nolan; A Ruben; R M Andrews
Journal:  Bull World Health Organ       Date:  2009-12-08       Impact factor: 9.408

2.  Ethnic disparity in pneumonia-specific mortality among children under 5 years of age in Sichuan Province of Western China from 2010 to 2017.

Authors:  Min Luo; Ziling Zhao; Linkun He; Bingzhong Su; Weixin Liu; Gang Zhang
Journal:  BMC Public Health       Date:  2019-12-23       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.